STOCK TITAN
  1. Home
  2. News
  3. INVA

Innoviva Inc - INVA STOCK NEWS

Welcome to our dedicated news page for Innoviva (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innoviva's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innoviva's position in the market.

News
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Rhea-AI Summary
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced positive Phase 3 data for oral zoliflodacin in treating uncomplicated gonorrhea, achieving a 90.9% cure rate and showing non-inferiority to the current standard of care. The collaboration with GARDP marks a milestone in addressing antibiotic-resistant strains, with plans for regulatory filings in the U.S. Results from the largest clinical trial for gonorrhea treatment show promising efficacy and safety profiles for zoliflodacin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Rhea-AI Summary
Armata Pharmaceuticals, Inc. secures a $35 million financing deal with Innoviva Strategic Opportunities LLC to advance phage-based therapeutic candidates targeting antibiotic-resistant infections. The funding will support ongoing Phase 2 trials and preparation for pivotal trials, showcasing confidence in the company's mission and clinical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
none
-
News
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Rhea-AI Summary
Innoviva, Inc. (NASDAQ: INVA) reported strong financial results for Q4 2023, with $69.6 million in GSK royalties, $19.7 million in net product revenues, and 35% YoY growth. Key achievements include the approval and launch of XACDURO® and positive Phase 3 data for zoliflodacin. The company also repurchased 1.1 million common stock for $15.4 million, showcasing a successful and transformational year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
earnings
News
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Innoviva, Inc. reported financial results for Q3 2023, including $57.0 million in GSK royalties and $13.7 million in net product revenues. They launched XACDURO® for pneumonia treatment and announced positive Phase 3 data for zoliflodacin in gonorrhea treatment. They also repurchased $11.0 million of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
Rhea-AI Summary
A Phase 3 study of oral zoliflodacin, a first-in-class antibiotic, has met its primary endpoint in treating drug-resistant Neisseria gonorrhoeae. The study found that zoliflodacin demonstrated non-inferiority to the current standard of care regimen. Positive results offer hope for patients and pave the way for the development of other antibiotics to address antimicrobial resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
clinical trial
-
News
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023
Rhea-AI Summary
Innoviva Specialty Therapeutics to present findings on XACDURO® and XERAVA® at IDWeek 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
News
Innoviva to Participate in the Cantor Global Healthcare Conference
Rhea-AI Summary
Innoviva CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
News
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
Rhea-AI Summary
Innoviva's subsidiary, Innoviva Specialty Therapeutics, announces the availability of XACDURO for the treatment of HABP/VABP caused by Acinetobacter infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
acquisition
-
News
Innoviva Appoints Stephen Basso as Chief Financial Officer
Rhea-AI Summary
Innoviva appoints Stephen Basso as CFO, effective August 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
earnings
Stock INVA logo
Innoviva Inc

Nasdaq:INVA

INVA Rankings

#2447 Ranked by Market Cap
#2623 Ranked by Stock Gains
N/A Ranked by Dividends

INVA Stock Data

925.02M
51.14M
1.59%
117.67%
17.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Brisbane

About INVA

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.